A Phase I/II Open-Label Study of Nimotuzumab in Combination With Nivolumab in Patients With Advanced Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Nimotuzumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 09 Jun 2017 Planned initiation date changed from 30 May 2017 to 30 Aug 2017.
- 04 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 30 May 2017.